• Explore /
  • Poster
  • / Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.

Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.

Abstract Poster

Authors

null

Manish R. Patel

Florida Cancer Specialists, Sarasota, FL

Manish R. Patel , Susanna Varkey Ulahannan , Scott James Weir , Robyn Wood , Tammy Ham , Crista Casey , Greg Reed , Prasad Dandawate , Prabhu Ramamoorthy , Michael Jay Baltezor , Roy A. Jensen , Benjamin L. Woolbright , John Arthur Taylor III, Shrikant Anant , Michael Dalton , Valentina Zhukova-Harrill , William McCulloch , Suzanne Fields Jones , Howard A. Burris III, Gerald Steven Falchook

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03348514

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 518)

Abstract #

518

Poster Bd #

J19

Abstract Disclosures

Similar Posters

First Author: Scott James Weir

First Author: John Arthur Taylor III

First Author: Philippe L. Bedard

Poster

2012 Genitourinary Cancers Symposium

Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors.

Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors.

First Author: Albert C. Lockhart